secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001193125-22-302356
Event type: debt
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.02, 2.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio raises ~$100M via equity and debt; affiliate converts $56.6M note into equity
--------------------------------------------------------------------------------

- Registered direct offering: 9,090,909 shares + warrants at $5.50 per unit, gross $50M.
- New $50M promissory note from Nant Capital (affiliated with Dr. Soon-Shiong) at Term SOFR + 8%, due Dec 2023.
- NantWorks converts ~$56.6M existing principal and accrued interest into common at $5.67/share.
- Pro forma cash and securities ~$160M after net proceeds of ~$96.4M from equity and debt.
- If fully exercised, warrants could yield up to $60M additional gross proceeds over two years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/0001193125-22-302356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000119312522302356/d413739d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-302356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer